Cellular Adjuvants for Viral Infection
US-2024299521-A1 · Sep 12, 2024 · US
Immunoadjuvant Compositions and uses Thereof
US2016193328A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016193328-A1 |
| Application number | US-201414911944-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 14, 2014 |
| Priority date | Aug 14, 2013 |
| Publication date | Jul 7, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an immunoadjuvant composition comprising at least adjuvant and at least one MyD88-dependent pathway agonist.
First claim
Opening claim text (preview).
1 . An immunoadjuvant composition comprising: a. at least one adjuvant and; b. at least one MyD88-dependent pathway agonist. 2 . An immunoadjuvant composition according to claim 1 wherein the adjuvant is selected from the group consisting of IFA, Alum, squalene and RIBI. 3 . An immunoadjuvant composition according to claim 1 wherein the MyD88-dependent pathway agonist is selected from the group consisting of a TLR4 agonist, a TLR9 agonist and a mixture thereof. 4 . An immunoadjuvant composition according to claim 3 wherein the TLR4 agonist is a lipopolysaccharide (LPS). 5 . An immunoadjuvant composition according to claim 3 wherein the TLR9 agonist is a CpG nucleic acid (ODN). 6 . An immunoadjuvant composition according to claim 5 wherein the TLR9 agonist is a CpG-B nucleic acid. 7 . An immunoadjuvant composition according to claim 2 comprising IFA and LPS. 8 . An immunoadjuvant composition according to claim 2 comprising IFA and CpG. 9 . An immunoadjuvant composition according to claim 2 comprising IFA and CpG-B. 10 . An immunoadjuvant composition according to claim 2 comprising RIBI and LPS. 11 . An immunoadjuvant composition according to claim 2 comprising RIBI and CpG. 12 . An immunoadjuvant composition according to claim 2 comprising RIBI and CpG-B. 13 . An immunoadjuvant composition according to claim 1 comprising at least one adjuvant, at least one TLR4 agonist and at least one TLR9 agonist. 14 . An immunoadjuvant composition according to claim 13 comprising the adjuvant IFA, the TLR4 agonist LPS and the TLR9 agonist CpG (ODN). 15 . An immunoadjuvant composition according to claim 14 comprising the adjuvant IFA, the TLR4 agonist LPS and the TLR9 agonist CpG-B. 16 . An immunoadjuvant composition according to claim 13 comprising the adjuvant ALUM, the TLR4 agonist LPS and the TLR9 agonist CpG. 17 . An immunoadjuvant composition according to claim 13 comprising the adjuvant ALUM, the TLR4 agonist LPS and the TLR9 agonist CpG-B. 18 . An immunoadjuvant composition according to claim 13 comprising the adjuvant RIBI, the TLR4 agonist LPS and the TLR9 agonist CpG. 19 . An immunoadjuvant composition according to claim 13 comprising the adjuvant RIBI, the TLR4 agonist LPS and the TLR9 agonist CpG-B. 20 . A method for inducing Tfh development and improving a humoral response in a subject in need thereof comprising administering to the subject a pharmacologically effective amount of an immunoadjuvant composition comprising a. at least one adjuvant and; b. at least one MyD88-dependent pathway agonist. 21 . A vaccine composition comprising an immunoadjuvant composition comprising a. at least one adjuvant and; b. at least one MyD88-dependent pathway agonist and one or more antigens.
Assignees
Inventors
Classifications
Inorganic adjuvants · CPC title
- A61K39/39Primary
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
Lipopolysaccharides; Lipid A; Monophosphoryl lipid A · CPC title
CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title
humoral response · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016193328A1 cover?
- The present invention relates to an immunoadjuvant composition comprising at least adjuvant and at least one MyD88-dependent pathway agonist.
- Who is the assignee on this patent?
- Inserm Inst Nat De La Santé Et De La Rech Médicale, Centre Nat Rech Scient, Université Paul Sabatier Toulouse Iii
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jul 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).